Display options
Cite
Atsukawa M, Tsubota A, Shimada N, et al. Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study. Hepat Mon. 2013;13(12):e14872doi: 10.5812/hepatmon.14872.
Atsukawa, M., Tsubota, A., Shimada, N., Kondo, C., Itokawa, N., Nakagawa, A., Hashimoto, S., Fukuda, T., Matsushita, Y., Kidokoro, H., Narahara, Y., Nakatsuka, K., Iwakiri, K., Kawamoto, C., & Sakamoto, C. (2013). Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study. Hepatitis monthly, 13(12), e14872. https://doi.org/10.5812/hepatmon.14872
Atsukawa, Masanori, et al. "Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study." Hepatitis monthly vol. 13,12 (2013): e14872. doi: https://doi.org/10.5812/hepatmon.14872
Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Narahara Y, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C. Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study. Hepat Mon. 2013 Dec 23;13(12):e14872. doi: 10.5812/hepatmon.14872. eCollection 2013. PMID: 24403915; PMCID: PMC3877658.
Copy Download .nbib Format: NLM
Share it on

Hepat Mon. 2013 Dec 23;13(12):e14872. doi: 10.5812/hepatmon.14872. eCollection 2013.

Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study.

Hepatitis monthly

Masanori Atsukawa, Akihito Tsubota, Noritomo Shimada, Chisa Kondo, Norio Itokawa, Ai Nakagawa, Satomi Hashimoto, Takeshi Fukuda, Yoko Matsushita, Hideko Kidokoro, Yoshiyuki Narahara, Katsuhisa Nakatsuka, Katsuhiko Iwakiri, Chiaki Kawamoto, Choitsu Sakamoto

Affiliations

  1. Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Chiba, Japan.
  2. Institute of Clinical Medicine and Research (ICMR), Jikei University School of Medicine, Kashiwa, Chiba, Japan.
  3. Division of Gastroenterology and Hepatology, Shinmatsudo Central General Hospital, Matsudo, Chiba, Japan.

PMID: 24403915 PMCID: PMC3877658 DOI: 10.5812/hepatmon.14872

Abstract

BACKGROUND: Serum vitamin D concentration is reported to show a decrease in older age. Patients with chronic hepatitis C (CHC) in Japan are older on average than those in Western countries. Moreover, the outcome of pegylated-interferon (PEG-IFN)/ ribavirin therapy combined with vitamin D in elderly patients is unclear.

OBJECTIVES: This pilot study explored the efficacy and safety of alfacalcidol as vitamin D source in PEG-IFN/ ribavirin combination therapy for elderly CHC patients infected with hepatitis C virus genotype 1b.

PATIENTS AND METHODS: Consecutive twenty CHC patients aged ≥ 65 years were enrolled in this pilot study. Fifteen patients met the inclusion criteria and received PEG-IFN/ ribavirin therapy combined with alfacalcidol. Four-week lead-in of oral alfacalcidol was conducted, and it was subsequently and concurrently administered in PEG-IFN/ ribavirin combination therapy (vitamin D group). Age, gender, and IL28B genotype-matched patients, who received PEG-IFN/ ribavirin alone, were saved as control group (n = 15) to compare the treatment outcome with the vitamin D group.

RESULTS: Subjects consisted of 14 males and 16 females, with a median age of 70 years (65-78). The serum 25 (OH) D3 concentration in females (20 ng/ml, 11-37) was significantly lower than males (27 ng/mL, 13-49) (P = 0.004). Sustained virological response (SVR) rates were 33.3% (5/15) in the control group and 80.0% (12/15) in the vitamin D group, respectively (P = 0.025). While no significant difference was shown in the (SVR) rate between the two groups among males (P = 0.592), in females the SVR rate was significantly higher in the vitamin D group (87.5%, 7/8) than the control group (25.0%, 2/8) (P = 0.041). The relapse rates in the groups with and without alfacalcidol were 7.7% (1/13) and 61.5% (8/13), respectively (P = 0.011). Interestingly, in females, the relapse in the control group was shown in 5 of 7 (71.4%), whereas in the vitamin D group the relapse rate was decreased (1/8, 12.5%) (P = 0.041). No specific adverse events were observed in the vitamin D group.

CONCLUSIONS: PEG-IFN/ ribavirin combined with alfacalcidol may be effective and safe in elderly CHC patients. In particular, concomitant administration of alfacalcidol may lead to a reduced relapse rate, and consequently improving the SVR rate in elderly females.

Keywords: 1-hydroxycholecalciferol; Aged; Hepatitis C, Chronic; Ribavirin; Vitamin D

References

  1. J Med Virol. 2007 Aug;79(8):1095-102 - PubMed
  2. J Immunol. 1986 Mar 15;136(6):2181-6 - PubMed
  3. Hepatology. 2012 Sep;56(3):884-93 - PubMed
  4. Gastroenterology. 2011 Mar;140(3):840-9; quiz e12 - PubMed
  5. Hepatology. 2011 Apr;53(4):1118-26 - PubMed
  6. Nat Genet. 2009 Oct;41(10):1100-4 - PubMed
  7. Hepatology. 2012 Oct;56(4):1231-9 - PubMed
  8. J Med Virol. 2006 Jan;78(1):83-90 - PubMed
  9. Hepatology. 2010 Apr;51(4):1158-67 - PubMed
  10. Nat Immunol. 2010 Apr;11(4):344-9 - PubMed
  11. N Engl J Med. 2009 Apr 30;360(18):1827-38 - PubMed
  12. J Med Virol. 2007 Nov;79(11):1686-95 - PubMed
  13. Xenobiotica. 2001 Oct;31(10):701-12 - PubMed
  14. Hepatology. 2011 Nov;54(5):1570-9 - PubMed
  15. Antivir Ther. 2011;16(7):1021-33 - PubMed
  16. Nature. 2009 Sep 17;461(7262):399-401 - PubMed
  17. Hepatology. 2010 Aug;52(2):518-27 - PubMed
  18. Dig Dis Sci. 2009 Jun;54(6):1317-24 - PubMed
  19. Hepatology. 1999 Apr;29(4):1124-30 - PubMed
  20. N Engl J Med. 2007 Jul 19;357(3):266-81 - PubMed
  21. J Hepatol. 2012 Jan;56(1):78-84 - PubMed
  22. World J Gastroenterol. 2011 Dec 21;17(47):5184-90 - PubMed
  23. N Engl J Med. 2011 Mar 31;364(13):1195-206 - PubMed
  24. Immunology. 1991 Aug;73(4):466-71 - PubMed
  25. Lancet. 2001 Sep 22;358(9286):958-65 - PubMed
  26. Hepatology. 2012 Mar;55(3):742-8 - PubMed
  27. Biochem Biophys Res Commun. 1984 May 31;121(1):277-83 - PubMed
  28. N Engl J Med. 2011 Mar 31;364(13):1207-17 - PubMed
  29. N Engl J Med. 1989 Sep 21;321(12):833-4 - PubMed
  30. N Engl J Med. 2002 Sep 26;347(13):975-82 - PubMed
  31. J Gastroenterol. 2013 Mar;48(3):382-90 - PubMed
  32. J Viral Hepat. 2009 Aug;16(8):586-94 - PubMed
  33. J Gastroenterol. 2004 Jul;39(7):668-73 - PubMed
  34. Nat Genet. 2009 Oct;41(10):1105-9 - PubMed
  35. Transpl Int. 2011 Jan;24(1):43-50 - PubMed
  36. N Engl J Med. 2011 Sep 15;365(11):1014-24 - PubMed

Publication Types